INSILICO(03696) receives Microsoft Azure support for open-source DORA, to reshape scientific research and content creation with multi-agent large models.

Clinical-stage biopharmaceutical technology company INSILICO(Insilico Medicine)(03696) announced today the launch of DORA Community Editiona comprehensive AI engine for scientific research and content creation, powered by generative artificial intelligence. The DORA Community Edition, initiated by INSILICO and launched with support from Microsoft, aims to enable more people to use cutting-edge research tools, promote global research collaboration, enhance transparency in scientific research, and accelerate innovation in biotechnology and academia. In today's rapidly evolving scientific landscape, writing various types of research documents, from literature reviews to patent applications and business reports, is often tedious and time-consuming. Born in July 2024 during a period of rapid development of large-scale models, DORA was developed by INSILICO as an advanced "Agentic AI" tool designed to simplify the writing process of academic papers and other research-related documents. Leveraging collaborative multi-agent AI, composite design prompts, pre-set content generation workflows, and INSILICO's proprietary database, it helps researchers efficiently generate a variety of professional-level documents and provide accurate references. With support from Microsoft and technological enhancements from Microsoft Foundry, INSILICO recently upgraded DORA's important features. The upgraded DORA can seamlessly integrate with various Foundry models, including the top-tier O3 Deep Research model, significantly improving the efficiency and quality of scientific content creation. The upcoming DORA Community Edition will be released under the permissive Apache 2.0 open-source license, providing friendly terms for commercial use and secondary development. Developers and researchers worldwide can access the open-source code of DORA through GitHub and start using it immediately at: https://github.com/insilicomedicine/DORA Dr. Alex Zhavoronkov, Founder and CEO of INSILICO, said, "We believe that the future of scientific discovery lies in collaboration, not isolation. By open-sourcing DORA, we are placing powerful AI tools directly into the hands of global innovators, with the hope of building a vibrant ecosystem that collectively enhances the rigor of research, continues to push the boundaries of biotechnology, and ultimately brings urgently needed therapies to patients faster." Elena Bonfiglioli, Global Health and Life Sciences Manager at Microsoft, said, "Microsoft is committed to working with partners and customers to drive and accelerate scientific discoveries beneficial to individuals, organizations, and industries globally. We are pleased to support INSILICO in open-sourcing DORA. By helping researchers retrieve, organize, and synthesize complex scientific information, DORA lowers the barriers to cutting-edge research and expands access to generative AI. As a partner in the Microsoft Discovery Preview program, we are working with INSILICO to promote deeper scientific collaboration and support customers in applying AI to make a truly impactful difference for people." In addition to the DORA Community Edition, INSILICO also offers a more comprehensive DORA SaaS version for users with higher-level, specialized needs. Compared to the open-source version, DORA SaaS provides access to pre-analyzed "protein-disease associations" reports from the INSILICO target discovery engine PandaOmics, offering deeper domain-specific insights; its integration with the INSILICO data warehouse supports real-time in-text citations. Furthermore, DORA SaaS includes a richer library of preset templates to support various types of scientific content creation. Users can also access and deploy DORA SaaS directly through the Microsoft Marketplace. As early as 2016, INSILICO was the first to systematically propose the concept of using generative AI to design innovative molecules in peer-reviewed journals, laying the groundwork for the later commercialized Pharma.AI platform. Since then, INSILICO has continued to integrate technological breakthroughs into Pharma.AI, evolving it into a generative AI integrated solution covering biology, chemistry, clinical development, and scientific research. Recently, INSILICO held the Pharma.AI Winter Online Seminar, announcing the latest developments in its software product portfolio and outlining its vision for advancing towards "pharmaceutical superintelligence." By integrating advanced AI and automation technologies, INSILICO has significantly improved the efficiency of early-stage drug discovery in practical applications, setting the benchmark for AI-driven drug discovery. Compared to the average 4.5-year timeline for traditional early drug discovery, INSILICO nominated 20 pre-clinical candidate compounds from 2021 to 2024, with an average time from inception to nomination of PCC ranging from 12 to 18 months, and each project requiring the synthesis and testing of approximately 60-200 molecules.